Physician scientist interested in brain cancer biology. Research Fellow @MGHPathology. Incoming resident @HarvardNeuroMDs.
Joined December 2019
- Tweets14
- Following102
- Followers67
- Likes122
Simon Gritsch retweeted
As the year winds down, we are excited to announce where our current PGY4s/NM3 will be continuing their post-residency journey! #NMatch2025 #Match2025 #neurology
Simon Gritsch retweeted
Excited to share our latest review in Trends in Molecular Medicine on the molecular evolution of CNS metastasis and its therapeutic implications! #CNSMetastasis #CancerResearch #PrecisionMedicine secure-web.cisco.com/1fdEIB_…
Simon Gritsch retweeted
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma dlvr.it/T6sdrv
Simon Gritsch retweeted
Lineage Differentiation Underlies #Glioma Response to IDH Inhibition, a summary of the study by @AvishaySpitzer, @GritschSimon, @M_Nomura, @KeithLigon5, D. Cahill, @MarioSuva, @TiroshLab et al.
bit.ly/3UBnXii
@WeizmannScience @MGHCancerCenter @DanaFarber @broadinstitute
Simon Gritsch retweeted
11/ Lastly, a highly recommended preview to our study beautifully written by Skylar Giacobetti and Howard Fine.
nitter.cf/Cancer_Cell/status/177…
Simon Gritsch retweeted
1/ We are extremely excited to share our new manuscript published @Cancer_Cell! Kudos to co-first authors @AvishaySpitzer, @GritschSimon and @M_Nomura for seminal work, to co-PIs @MarioSuva, Dan P. Cahill and @KeithLigon5 and to all contributors.
Online Now: Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma dlvr.it/T57X2F
Simon Gritsch retweeted
Out today @Cancer_Cell from our teams: IDH inhibitors (like #Vorasidenib) induce differentiation in samples from treated #oligodendroglioma patients & NOTCH1 mutations may aid resistance. Seminal work by 1stauthors @AvishaySpitzer @GritschSimon @M_Nomura authors.elsevier.com/a/1it88…
Simon Gritsch retweeted
Late breaking at #ASCO23: Mutations in isocitrate dehydrogenase 1 or 2 are common in low-grade glioma. The IDH inhibitor vorasidenib improved progression-free survival as compared with placebo. Full results of the INDIGO trial: nej.md/3N8N5dU
Simon Gritsch retweeted
Quick reminder for our upcoming talk by @humsav @venkatesh_lab. Register below! #cancerneuroscience
We are pleased to announce the next speaker of our #cancerneuroscienceseminarseries, @humsav! Register here with your institutional email address to listen to this brilliant talk!
us06web.zoom.us/meeting/regi…
@BrighamWomens @harvardmed
Simon Gritsch retweeted
Now online! Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy!
#ScienceTwitter #CancerResearch
bit.ly/3uwzL9n
Simon Gritsch retweeted
Excited for the next speaker in our BWH/Stanford Cancer Neuroscience Seminar Series! Dr. Frank Winkler will be providing his groundbreaking insights on Malignant Networks in the Brain. Register here: tinyurl.com/2pkcrcv4
Simon Gritsch retweeted
The 5th edition of the WHO classification of CNS tumors is online today! Great timing with @NeuroOnc 2021 meeting! tumourclassification.iarc.wh…
Simon Gritsch retweeted
Thrilled to share our preprint by @AvishaySpitzer, @GritschSimon, a close collaboration with @TiroshLab, Daniel Cahill and @KeithLigon5, demonstrating that mutant-IDH inhibitors (mIDHi) act as differentiation therapy in Oligodendroglioma (OG). medrxiv.org/cgi/content/shor…
Simon Gritsch retweeted
Welcome to our Nm0s!!!
I feel so lucky that I’ll be surrounded by this amazing group of @harvardneuromds residents for the next 4 years. A great orientation week of getting to know everyone!
